Treatment of IgG4-related pachymeningitis in a patient with steroid intolerance: The role of early use of rituximab

Vadim Gospodarev, Justin Câmara, Vikram Chakravarthy, Arie Perry, Matthew Wood, Robin Dietz, Jun Wang, Kenneth De Los Reyes, Ravi Raghavan

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

IgG4-related pachymeningitis is a serious inflammatory condition that can present with symptoms of mass effect and focal deficits. The first-line therapy is steroids and second-line is chemotherapy (methotrexate, azathioprine, etc.). We describe a patient with IgG4-related pachymeningitis in whom steroid use was contraindicated and methotrexate was ineffective. During the course of treatment, the patient presented to the emergency department with receptive and expressive aphasia, slurred speech, right-sided neglect, and loss of sensation. After a single infusion of rituximab and anticonvulsants, her symptoms resolved. Our unique case suggests that patients with IgG4-related pachymeningitis might benefit from early initiation of rituximab.

Original languageEnglish (US)
Pages (from-to)62-65
Number of pages4
JournalJournal of Neuroimmunology
Volume299
DOIs
StatePublished - Oct 15 2016

Keywords

  • IgG4-related diseases
  • IgG4-related pachymeningitis
  • methotrexate
  • rituximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Treatment of IgG4-related pachymeningitis in a patient with steroid intolerance: The role of early use of rituximab'. Together they form a unique fingerprint.

  • Cite this

    Gospodarev, V., Câmara, J., Chakravarthy, V., Perry, A., Wood, M., Dietz, R., Wang, J., De Los Reyes, K., & Raghavan, R. (2016). Treatment of IgG4-related pachymeningitis in a patient with steroid intolerance: The role of early use of rituximab. Journal of Neuroimmunology, 299, 62-65. https://doi.org/10.1016/j.jneuroim.2016.08.009